CytoDyn Names Robert E. Hoffman CEO as Jacob Lalezari Moves to Research Role
CytoDyn appointed Hoffman CEO effective October 20, 2026. Lalezari resigned as CEO on the same date and will become Head of Research and Translational Sciences.
CytoDyn appointed Hoffman CEO effective October 20, 2026. Lalezari resigned as CEO on the same date and will become Head of Research and Translational Sciences.